{
 "query": "atezolizumab",
 "ingredient": "atezolizumab",
 "slug": "atezolizumab",
 "rxcui": "1792776",
 "brands": [
  "Tecentriq"
 ],
 "names": [
  "atezolizumab"
 ],
 "classes": [
  {
   "id": "L01FF",
   "name": "PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors"
  }
 ],
 "alternatives": [
  "avelumab",
  "cemiplimab",
  "dostarlimab",
  "durvalumab",
  "nivolumab",
  "pembrolizumab",
  "retifanlimab",
  "tislelizumab",
  "toripalimab"
 ],
 "label": {},
 "faers": {
  "total": 38914,
  "serious": 37160,
  "death": 9856,
  "hospitalization": 16595,
  "primary_suspect": 38902,
  "top_reactions": [
   [
    "Death",
    4271
   ],
   [
    "Off Label Use",
    3584
   ],
   [
    "Disease Progression",
    2163
   ],
   [
    "Pyrexia",
    1760
   ],
   [
    "Diarrhoea",
    1716
   ],
   [
    "Fatigue",
    1503
   ],
   [
    "Anaemia",
    1364
   ],
   [
    "Pneumonia",
    1143
   ],
   [
    "Decreased Appetite",
    1112
   ],
   [
    "Hypothyroidism",
    1089
   ],
   [
    "Nausea",
    1066
   ],
   [
    "Dyspnoea",
    1036
   ],
   [
    "Hypertension",
    1000
   ],
   [
    "Pneumonitis",
    970
   ],
   [
    "Febrile Neutropenia",
    965
   ]
  ],
  "by_year": {
   "2019": 2670,
   "2020": 3406,
   "2021": 5291,
   "2022": 5805,
   "2023": 5878,
   "2024": 5155,
   "2025": 4659,
   "2026": 2204
  },
  "by_year_primary": {
   "2019": 2670,
   "2020": 3406,
   "2021": 5289,
   "2022": 5804,
   "2023": 5878,
   "2024": 5155,
   "2025": 4656,
   "2026": 2198
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 2,
  "nda": 0,
  "anda": 0,
  "first_approval": "20160518",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 0,
  "labeling_recent": 0,
  "sponsors": [
   "GENENTECH INC"
  ],
  "unapproved": false,
  "first_approval_fmt": "05/18/2016"
 },
 "trials": {
  "total": 1006,
  "completed": 322,
  "terminated": 191,
  "with_results": 242,
  "industry": 595,
  "phase3": 134,
  "results_share": 0.7515527950310559,
  "terminated_share": 0.18986083499005965
 },
 "pubmed": {
  "rct": 211,
  "meta": 34,
  "recent_rct": 161,
  "cochrane": []
 },
 "payments": {
  "year": "2024",
  "usd": 49937904.63,
  "records": 2594,
  "by_name": [
   [
    "Tecentriq",
    49937904.63
   ]
  ],
  "names_checked": [
   "atezolizumab",
   "Tecentriq"
  ],
  "source": "bulk-index"
 },
 "partd": {
  "year": "2024",
  "claims": 2145,
  "beneficiaries": 410,
  "spend": 22975154.72,
  "by_brand": [
   {
    "brand": "Tecentriq",
    "claims": 2145,
    "per_claim": 10711.027841,
    "is_generic": false
   }
  ],
  "per_claim": 10711.027841491841
 },
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": true,
  "status": "AddedToEml",
  "name": "atezolizumab",
  "matched": "atezolizumab",
  "stewardship": []
 },
 "exposure": null,
 "scores": {
  "safety": {
   "score": 83,
   "letter": "B",
   "why": [
    "Death appears in 2.8x the share of reports seen across all of FAERS (-12)",
    "Off-label use is among the five most-reported items: widely used beyond its approved evidence (-5)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 68,
   "letter": "C",
   "why": [
    "211 randomized trials and 34 systematic reviews/meta-analyses indexed in PubMed",
    "On the WHO Model List of Essential Medicines (shown for context; no score effect)",
    "No Cochrane review found (-5)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 100,
   "letter": "A",
   "why": [
    "No recalls on record since 2016"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 55,
   "letter": "D",
   "why": [
    "Pharma paid doctors $49,937,905 tied to this drug last year (-45)",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 70,
   "letter": "C",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "9 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 76,
 "grade": "B",
 "questions": [
  "The most-reported problems in FDA's adverse event data are death, disease progression, pyrexia. How would we recognize and handle those?",
  "Off-label use is among the most-reported items for this drug. Is my use on-label, and if not, what evidence supports it?",
  "Why this one over avelumab, cemiplimab, dostarlimab? What would make you pick one of those instead?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "The manufacturer pays physicians heavily to promote this drug. Have you received anything from them?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}